ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis

Li, Aihua; Su, Xiaorong; Hu, Shanshan*; Wang, Yong*南方医科大学; 上海交通大学; y
Diabetes Research and Clinical Practice2023-4DOI: 10.1016/j.diabres.2023.110605
6被引8阅读
引用收藏
分享

摘要

Objectives: To investigate the efficacy and safety of oral semaglutide 7 and 14 mg, the only orally delivered glucagon-like peptide-1 (GLP-1) receptor agonist tablet approved for type 2 diabetes mellitus (T2DM) patients. Methods: Search several databases for randomized controlled trials (RCTs) of oral semaglutide in patients with T2DM from inception through May 31, 2021. The primary outcomes included change from baseline in hemo-globin A1c (HbA1c) and body weight. Risk ratios (RR), mean differences (MD), and 95% confidence intervals (CI) were calculated to evaluate the outcomes. Results: This meta-analysis included 11 RCTs with a total of 9821 patients. Compared with placebo, semaglutide 7 and 14 mg reduced HbA1c by 1.06% (95% CI, 0.81-1.30) and 1.10% (95% CI, 0.88-1.31), respectively. While in comparison with other antidiabetic agents, semaglutide 7 and 14 mg reduced HbA1c by 0.26% (95% CI, 0.15-0.38) and 0.38% (95%CI, 0.31-0.45). Both doses of semaglutide could significantly reduce body weight. Semaglutide 14 mg did increase the incidence of medication discontinuation and gastrointestinal events (nausea, vomiting and diarrhea). Conclusion: Once-daily semaglutide 7 and 14 mg can significantly lowered HbA1c and body weight in patients with T2DM, and this effect increases with dose. Significantly, more gastrointestinal events occurred with sem-aglutide 14 mg.

学科与关键词

关键词
Oral semaglutideMeta-analysisType 2 diabetes mellitusSystematic review
相关
加载中…
  • Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
    Xie, Zeyu; Hu, Jia; Gu, Hangye; Li, Mengting; Chen, Jisheng*Frontiers in Endocrinology, 2023, 14: 1244432.被引 1
  • Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
    Xie, Zeyu; Yang, Sensen; Deng, Weishang; Li, Jinjian; Chen, Jisheng*Clinical Epidemiology, 2022, 14: 1463-1476.被引 8
  • Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
    Zhong, Ping; Zeng, Hai; Huang, Miaochun; Fu, Wenbin*; Chen, Zhixia*ENDOCRINE, 2022, 75(3): 718-724.被引 23
查看全部 →

发表信息

论文状态
公开发表
期刊
Diabetes Research and Clinical Practice
发表日期
2023-04
卷期
第 198 卷
页码
110605
DOI
10.1016/j.diabres.2023.110605
语言
ENGLISH
成果收录
SCIE
资助标注
Guangdong Yiyang Healthcare Charity Foundation [JZ2022010]

作者

  • L

    Li, Aihua (第一作者)

    southern med univ

  • S

    Su, Xiaorong

    southern med univ

查看全部 4 位作者收起作者
  • H

    Hu, Shanshan (通讯)

    shanghai jiao tong univ

  • W

    Wang, Yong (通讯)

    southern med univ · new

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417